Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesDiabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options
American Journal of Medicine, 08/28/08
Aneja A et al. - Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of coronary artery disease and hypertension. Therapeutic agents specifically targeting processes that lead to these pathophysiologic changes are in the early stages of development. Although glycemic control and early administration of neurohormonal antagonists remain the cornerstones of therapeutic approaches, newer treatment targets are currently being explored.
| Previous Article | Next Article |
Today in Diabetes...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of androgen deprivation therapy on cardiovascular disease and diabetes
Journal of Clinical Oncology, 06/12/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Sponsor
Article Search
Sponsor